Is Iovance Biotherapeutics, Inc. (IOVA) a Buy, Sell, or Hold?
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$3.93 USD
-$0.11 (-2.72%)
- Volume
- 13.35M
- Average Volume
- 14.27M
- Market Capitalization
- $1.41B
- P/E Ratio
- -4.27
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $5.63
- Year Low
- $1.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.60
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Frederick G. Vogt |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IOVA |
| CUSIP | 462260100 |
| CIK | 0001425205 |
| Web | https://www.iovance.com |
| Phone | 650 260 7120 |
| Currency | USD |
| Employees | 975 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.60 |
| Quick Ratio | 3.15 |
| Cash Ratio | 1.52 |
Sales & Book Value
| Annual Sales | $263.5M |
| Price / Sales | 4.92 |
| Cash Flow | -0.73 |
| Price / Cash Flow | -4.61 |
| Price / Book | 2.28 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -21.40% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 20 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.09 |
| Trailing P/E Ratio | -4.27 |
| PEG Ratio | -0.14 |
| P/E Growth | -0.14 |
| Net Income | $-390.98M |
| Net Margin | -123.90% |
| Pretax Margin | -124.21% |
| Return on Equity | -50.17% |
| Return on Assets | -38.23% |
Financials Score
| AltmanZ Score | -0.50 |
| Piotroski Score | 3.00 |
| Working Capital | 337.08M |
| Total Assets | 925.66M |
| Ebit | -354.76M |
| Market Cap | 1.47B |
| Total Liabilities | 203.91M |
Poll Results
About Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Bi ... otherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
This Stock Is Up 74% This Year: Is It Too Late to Buy?
2026-07-08 18:45:00
The biotech is clearly innovative, but sometimes that's not enough.
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-07-04 09:44:59
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-23 19:33:07
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-06-19 17:15:00
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance's common stock to twenty-seven new, non-executive employees.
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
2026-06-17 11:31:00
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
2026-06-03 16:05:00
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy
2026-06-02 00:15:00
Iovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the past five years. Past issues with dilution and disappointment may be clearing up, given recent sales growth and the company's current cash position.
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
2026-06-01 12:32:25
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the company said account for more than 100,000 US deaths a year. The clearance allows Iovance to begin clinical work on IOV-5001 and marks the platform's move beyond its current focus and into the solid tumor setting.
Frequently Asked Questions
-
What is the current Iovance Biotherapeutics, Inc. (IOVA) stock price?
-
Iovance Biotherapeutics, Inc.(NASDAQ:IOVA) stock price is $3.93 in the last trading session. During the trading session, IOVA stock reached the peak price of $5.63 while $1.76 was the lowest point it dropped to. The percentage change in IOVA stock occurred in the recent session was --2.72% while the dollar amount for the price change in IOVA stock was -$-0.11.
-
IOVA's industry and sector of operation?
-
The NASDAQ listed IOVA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IOVA?
-
Brian Gastman | Executive Vice President of Translational Medicine & Research
Friedrich Graf Finckenstein | Chief Medical Officer
Kevin Smyth | Executive Vice President of Quality
Corleen Roche | Chief Financial Officer
Daniel G. Kirby | Chief Commercial Officer -
How many employees does IOVA have?
-
Number of IOVA employees currently stands at 975. IOVA operates from 825 Industrial Road, San Carlos, CA 94070, US.
-
Link for IOVA official website?
-
Official Website of IOVA is: https://www.iovance.com
-
How do I contact IOVA?
-
IOVA could be contacted at phone #650 260 7120 and can also be accessed through its website. IOVA operates from 825 Industrial Road, San Carlos, CA 94070, US.
-
How many shares of IOVA are traded daily?
-
The average number of IOVA shares traded daily for last 3 months was 14.27M.
-
What is the market cap of IOVA currently?
-
The market value of IOVA currently stands at $1.41B with its latest stock price at $3.93